SOPH SOPHiA GENETICS SA

Nasdaq sophiagenetics.com


$ 4.59 $ 0.00 (0 %)    

Wednesday, 12-Nov-2025 07:15:35 EST
QQQ $ 624.96 $ 0.00 (0 %)
DIA $ 480.41 $ 0.00 (0 %)
SPY $ 685.11 $ 0.00 (0 %)
TLT $ 89.81 $ 0.00 (0 %)
GLD $ 380.53 $ 0.00 (0 %)
$ 4.62
$ 4.57
$ 4.19 x 52
$ 4.60 x 50
-- - --
$ 2.58 - $ 5.30
74,037
na
308.09M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-maintains-buy-on-sophia-genetics-raises-price-target-to-7

BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $6 to $7.

 sophia-genetics-and-adam-innovations-partner-to-launch-ai-powered-liquid-biopsy-genomic-testing-and-develop-companion-diagnostic-for-cancer-care-in-japan

- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technolog...

 2-under-the-radar-health-tech-stocks-with-surging-momentum-scores

Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.

Core News & Articles

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOP...

 sophia-genetics-affirms-fy2025-sales-guidance-of-72000m-76000m-vs-74200m-est-projects-adjusted-ebitda-loss-between-35m-39m

Sophia Genetics (NASDAQ:SOPH) affirms FY2025 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 mill...

 sophia-genetics-q2-eps-033-misses-023-estimate-sales-18323m-beat-17480m-estimate

Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION